PNTG · Pennant Group, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. Pennant (PNTG) delivered strong Q2 2026 results, raising full-year 2026 guidance for revenue, adjusted EBITDA, adjusted EBITDA prior to NCI, and adjusted EPS, with the home health proposed 2027 rate and ongoing Southeast acquisition transition underpinning the outlook.
- + Strong Q2 revenue and adjusted EBITDA growth versus prior year quarter
- + 2027 proposed home health rule includes a 2.4% rate increase (modeled as 1.7%) after four consecutive years of base rate cuts
- + Home health and hospice segment revenue up 43.2% and segment adjusted EBITDA up 48.2% with 70 bps same-store margin improvement
- + Strong same-store organic growth: same-store hospice ADC +10.8%, same-store Medicare home health admissions +13.6%
- − Home health revenue per episode declined 1.9% year over year
- − Ongoing integration disruption from largest acquisition in company history continues through October
- − Outstanding credit facility balance of $201.9 million; debt increased driven by Hartford investment
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PNTG
this stock
Pennant Group, Inc.
|
$1.42B | +38.5% | +36.3% | 44.8 | 3.0% |
|
HCA
HCA Healthcare, Inc.
|
$96.64B | -8.6% | +7.1% | 15.0 | 2.9% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$29.92B | -11.6% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$20.91B | +28.6% | +0.9% | 10.0 | 2.5% |
|
EHC
Encompass Health Corp
|
$12.18B | +14.5% | +10.5% | 20.1 | 3.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PNTG | -1.6% | +3.3% | +23.1% | +6.1% | +38.5% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -1.0% | +3.2% | +11.0% | +6.7% | +26.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.